What does cytogenetic analysis of bone marrow provide in the context of AML?

What does cytogenetic analysis of bone marrow provide in the context of AML?

• A. Information on treatment efficacy
• B. Prognosis assessment
• C. Determination of infection status
• D. Estimation of survival rates

Answer: (B)

Cytogenetic analysis of bone marrow plays a crucial role in the assessment of prognosis for patients with Acute Myeloid Leukemia (AML). This analysis involves examining the chromosomes within the bone marrow cells to identify specific genetic abnormalities associated with different subtypes of AML. Certain chromosomal changes, such as translocations or deletions, can be indicative of the disease's aggressiveness and responsiveness to treatment, thus directly influencing the prognosis and expected outcomes for the patient. For instance, the presence of certain cytogenetic abnormalities, like the t(15;17) translocation in acute promyelocytic leukemia (APL), is associated with a better response to specific therapies, while other changes may indicate a poorer prognosis. Therefore, by evaluating the genetic makeup of the leukemia cells, clinicians can make more informed predictions about disease progression and tailor treatment plans accordingly.

Cytogenetic analysis of bone marrow plays a crucial role in the assessment of prognosis for patients with Acute Myeloid Leukemia (AML). This analysis involves examining the chromosomes within the bone marrow cells to identify specific genetic abnormalities associated with different subtypes of AML. Certain chromosomal changes, such as translocations or deletions, can be indicative of the disease's aggressiveness and responsiveness to treatment, thus directly influencing the prognosis and expected outcomes for the patient.

For instance, the presence of certain cytogenetic abnormalities, like the t(15;17) translocation in acute promyelocytic leukemia (APL), is associated with a better response to specific therapies, while other changes may indicate a poorer prognosis. Therefore, by evaluating the genetic makeup of the leukemia cells, clinicians can make more informed predictions about disease progression and tailor treatment plans accordingly.